Saturday 17 October 2026
Export ASBP’s income statement to Excel — free account
Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
8.78
0.14
+1.62%
Follow ASBP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,032.15%) | 576.00% | 618.48% | 228.48% |
+8 more TTM periods Free account |
|
| (152.09%) | (259.01%) | (3,353.07%) | (453.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(93.80%) | (296.68%) | 389.78% | 179.26% | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(6.92) | (39.63) | (98.87) | (85.34) | |
Free Cash Flow |
(7.19) | (6.21) | (4.92) | (3.52) | |
| Other line items | |||||
Cash ROIC |
(30.04%) | (63.86%) | 190.69% | 107.23% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.09 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
2,903.57 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
861.72 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
857.83% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6,373.90% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
161.21% | 0.00% | 0.00% | — | |
Interest Coverage |
— | (0.55) | (2.27) | (6.04) | |
Operating CF/Net income |
0.65 | 0.53 | 0.20 | 0.17 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.09 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.92) | (39.63) | (98.87) | (85.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates